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human skeletal muscle cells; transforming growth factor-␤-like molecules; Smad signaling; mammalian target of rapamycin complex signaling; transducer of regulated Ca 2ϩ -responsive element-binding protein activity; S6 kinase; MuRF1; MAFbx; atrogin; MuRF-1 SKELETAL MUSCLE ATROPHY-a loss of muscle mass and fiber size-is a hallmark of cachexia, a severe comorbidity seen in congestive heart failure, chronic obstructive pulmonary disease, closed head trauma, and severe burns (12) . Recently, two markers of skeletal muscle atrophy have been characterized, the muscle-specific E3 ubiquitin ligases muscle RING-finger 1 (MuRF1) and muscle atrophy F-box (MAFbx; also called atrogin -1) . MuRF1 and MAFbx have been demonstrated to be upregulated in at least 13 distinct models of skeletal muscle atrophy (3, 6 -8, 11, 13, 17, 19, 22, 24, 28, 40, 41, 47, 50) , in both rodents and humans (34, 42) . For example, it was recently demonstrated that in the acute atrophy that occurs in diaphragm muscle, in patients on mechanical ventilation, MAFbx expression increased more than twofold, and MuRF1 was increased by greater than fivefold (27) . The expression of these E3 ligases MuRF1 and MAFbx can be opposed by activating the insulin-like growth factor 1 (IGF-1)/Akt pathway (24) . Akt phosphorylates and thus inhibits the family of FoxO transcription factors, which are required for MuRF1 and MAFbx upregulation (43, 48) . The IGF-1/Akt pathway also induces skeletal muscle hypertrophy by increasing protein synthesis pathways (21, 33, 38) . IGF-1 modulation of protein synthesis operates via Akt/mammalian target of rapamycin (mTOR) signaling. mTOR can be activated both by growth factor signaling, via Akt, and by the presence of branched chain amino acids. There are two distinct mTOR complexes, called TORC1 and TORC2 (2) . TORC1 includes a protein called RAPTOR (regulatory-associated protein of mTOR); this complex can be inhibited by rapamycin (45) . In a second, rapamycinindependent, complex, TORC2, mTOR is complexed with a protein called RICTOR (rapamycin-insensitive companion of mTOR), which has been characterized as being able to phosphorylate Akt on serine 473, in a positive feedback mechanism (44) . The roles of RICTOR and RAPTOR in myostatin or transforming growth factor-␤ (TGF-␤) inhibition of muscle differentiation have not been established.
In addition to IGF-1, other secreted proteins have been demonstrated to perturb skeletal muscle size. Myostatin, also called growth differentiation factor 8 (GDF-8), is a TGF-␤ family member and a negative regulator of muscle mass (26) . Myostatin's effect was demonstrated in studies with mice that were made null for the myostatin gene (30) , and also by correlating increases in muscle mass that were observed in strains of cattle with a loss of myostatin (14, 18, 31) ; the loss of myostatin resulted in a more than doubling in muscle mass. It has been suggested that other TGF-␤ superfamily molecules, distinct from myostatin, play a role in modulating skeletal muscle size, since myostatin Ϫ/Ϫ mice that are mated with mice that are transgenic for follistatin (TG follistatin ), which is capable of inhibiting not only myostatin, but also its close relative GDF-11, and other TGF-␤ molecules such as the activins, resulted in an even greater increase in muscle size (33) .
In vitro studies with myostatin have been performed on rodent cells. In these studies, it has been shown that myostatin can block the differentiation of myoblasts into myotubes (23, 29, 37, 51) . Experiments both in vitro and in vivo have demonstrated that myostatin signals by first binding the type II activin receptor, IIb, which then allows for interaction with type I receptors ALK4 or ALK5 (49) . The binding of myostatin to these receptor complexes results in the phosphorylation and activation of the transcription factors Smad2 and Smad3, which translocate to the nucleus upon phosphorylation (35) .
In the current study, the myostatin signaling pathways downstream of the Smads are further elucidated.
EXPERIMENTAL PROCEDURES
Cell culture and treatment. Human skeletal muscle cells (HuSkMC; Lonza) were cultured in growth medium (GM) consisting of skeletal muscle basal medium (skBM; Lonza) supplemented with 20% FCS (Amimed). Differentiation was initiated 24 to 48 h after seeding by changing to serum-free differentiation medium consisting of skBM. For small interfering RNA (siRNA) experiments, cells were transfected 24 h after seeding in GM and differentiation was initiated after another 24 h. For reporter gene experiments, HuSkMC were transfected 24 h after seeding with pGL3-CAGA12-luc in serum-free skBM for 4 h and then returned to GM for another 36 h, before compound addition. If effects on HuSkMC differentiation were assessed, compounds were added at the onset of differentiation and cells were differentiated into myotubes for up to 72 h. If effects on mature HuSkMC myotubes were assessed, compounds were added on 3-day differentiated myotubes for additional up to 48 h. For human embryonic kidney (HEK)-293T cells stably transfected with pGL3-CAGA12-luc, cells were seeded in serum-reduced medium (2% FCS) for 24 h, medium was removed, and cells were stimulated with a 1:1 mixture of mouse serum and serum-reduced medium (2% FCS) in the presence of 500 ng/ml Fc-TGF-␤ R (to measure myostatin/GDF-11 activity) for another 24 h.
Biochemicals and antibodies. Myostatin, TGF-␤ 1, activin A, activin AB, activin B, growth differentiation factor 11 (GDF-11), bone morphogenetic factor 2 (BMP-2), bone morphogenetic factor 7 (BMP-7), human TGF-␤ RIIb/Fc chimera (Fc-TGF-␤ R), and follistatin were from R&D Systems; long-R3-insulin-like growth factor I (IGF-I) and SB-431542 (SB) were from Sigma-Aldrich. Myostatin propeptide D76A was kindly provided by the Novartis Biologic Units (M. Zurini). Stock solutions were prepared either in phospho-buffered saline (PBS) supplemented with 0.1% bovine serum albumin (BSA; follistatin, Fc-TGF-␤ R, activin A, activin AB, and activin B), in 10 mM HCl (IGF-I), in 4 mM HCl supplemented with 0.1% BSA (myostatin, TGF-␤1, BMP-2, BMP-7, and GDF-11), or in dimethyl sulfoxide (SB). For immunostaining, primary antibody against myosin heavy chain (MyHC; clone A4.1025) was from Upstate, and secondary antibody [Alexa Fluor 488 F (AB')] was from Invitrogen. For Western blot analysis, antibodies against phospho-Smad2 (Ser465/ 467) (pSmad2) and MyoD were from Upstate; antibodies against ␣-tubulin were from Sigma-Aldrich; antibodies against myogenin were from BD Transduction Laboratories; and antibodies against Smad2/3 [Smad2/3, phospho-Akt (Ser473)] (pAkt, catalog no. 9271), Akt, phospho-p70 S6 kinase (Thr389) (pp70), and phospho-FoxO1 (Thr24)/FoxO3 (Thr32) (pFoxO) were from Cell Signaling. As secondary antibodies, goat anti-rabbit IgG horseradish peroxidase (HRP) and goat anti-mouse IgG HRP from SuperSignal West Femto Maximum Sensitivity Substrate (Pierce) were used. For ELISA, as capture antibodies, pSmad2 (Upstate) or Smad2/3 (Cell Signaling) were used. As detection antibody, Smad2/3 (BD Transduction Laboratories) were used, and as secondary antibody, anti-mouse IgG HRP was used (Cell Signaling).
Western blot analysis. For HuSkMC, lysis buffer consisting of phosphosafe extraction reagent (Novagen) supplemented with 1% protease inhibitor cocktail (Sigma-Aldrich) was added. Homogenates were centrifuged for 10 min at 4°C (14,000 rpm). Supernatants were collected, and protein contents were measured using bicinchoninic acid (BCA) kit for protein determination (Sigma-Aldrich). Samples were diluted in SDS-PAGE sample buffer and denatured for 5 min at 95°C. Equal amounts of protein were loaded per lane of 10% Bis-Tris NuPAGE gels, electrophoresed, and then transferred onto nitrocellulose membranes. Membranes were blocked in TBS with 5% (wt/vol) nonfat milk powder. Primary antibodies were incubated in Trisbuffered saline (TBS) with 0.1% Tween 20 and either 3% BSA (pAKT, AKT, MyoD, myogenin, and tubulin), 5% (Smad2/3, pp70S6, and pFoxO), or 5% nonfat milk (pSmad2), and secondary antibodies were incubated in TBS with 0.1% Tween 20, 0.05% SDS, and 5% nonfat milk. Immunoreactivity was detected by SuperSignal West Femto Maximum Sensitivity Substrate and exposed to film.
RNA analysis. RNA was isolated using a RNEasy Mini Kit (Qiagen), per the manufacturer's protocol. cDNA synthesis was performed using a QuantiTect Kit (Qiagen). Quantitative real-time PCR was performed using an Applied Biosystems 7500 FAST real-time PCR machine. The Taqman probe sets MuRF-1 (Hs00261590_m1), MAFbx (Hs00369709_m1), MyoD (Hs00159528_m1), myogenin (Hs00231167_m1), Smad2 (Hs00998186_m1), and Smad3 (Hs00232222_m1) were purchased from Applied Biosystems.
siRNA. The siRNA pools designed against Smad2, Smad3, RICTOR, RAPTOR, and a control (NTC) targeting a not known mammalian sequence together with DharmaFECT 1 from Dharmacon were used. Final siRNA concentrations were 100 nM.
Immunostaining. After washing with cytoskeleton stabilizing buffer (CSB), consisting of 80 mM PIPES, 5 mM EGTA, 1 mM MgCl 2, 40 g/l PEG3500 in distilled water (pH 7.4), cells were fixed with 4% paraformaldehyde in CSB. Cells were then permeabilized with 0.2% Triton in CSB, and nonspecific binding was blocked with normal goat serum (Zymed) followed by incubation with MyHC diluted in PBS and subsequently with Alexa Fluor 488 F (AB') diluted in PBS. Cells were mounted with ProLong Gold antifade reagent with DAPI (Invitrogen).
Reporter gene assays. The reporter plasmid pGL3-CAGA12-luc, containing the TGF-␤-responsive reporter gene construct CAGA12-luc cloned into the reporter construct pGL3 (Promega), and HEK-293T cells stably transfected with this reporter plasmid were kindly provided by C. Lu (Developmental and Molecular Pathways, Novartis Pharma). Transfection in HuSkMC was performed using 50 ng DNA (pGL3-CAGA12-luc), PLUS reagent (Invitrogen), and Lipofectamine reagent (Invitrogen). Reporter gene activity was measured using Britelite Plus (Perkin Elmer); chemiluminescence was read using a Spectramax M5 (Molecular Devices).
Creatine kinase activity assay. Cells were washed three times with PBS and then lysed with reporter lysis buffer (Promega) and stored until measurement at Ϫ80°C. Muscle lysates were prepared in lysis buffer consisting of phosphosafe extraction reagent supplemented with 1% protease inhibitor cocktail. Creatine kinase (CK) activity was measured using the CK (IFCC) reagent (Thermo Electron). The CK reagent was prepared according to the manufacturers instructions. Lysates were adjusted to room temperature, CK reagent was added, and absorbance was immediately read at 340 nm for 20 min; reading interval was 1 min. CK standard curves were freshly prepared using CK from rabbit muscle (Roche Diagnostics). Protein content was determined using BCA kit.
ELISA. For Smad2, ELISA plates were coated with capture antibodies (pSmad2 or Smad2/3) overnight at 4°C. Nonspecific binding was blocked with PBS containing 5% nonfat milk for 2 h. Cell lysates diluted 1:10 in PBS with 5% nonfat milk containing 0.05% Tween 20 were added and incubated overnight at 4°C. Detection antibody (Smad2/3) was added for 1.5 h at room temperature followed by incubation with secondary antibody (anti-mouse IgG) 1 h at room temperature. After addition of SuperSignal ELISA Femto Maximum Sensitivity substrate (catalog no. 37074; Pierce), chemiluminescence was read using a Spectramax M5 (Molecular Devices).
For Akt, Pathscan pAkt and Akt ELISA kits from Cell signaling were used per manufacturer's protocol.
Diameter measurement. To analyze diameters, four pictures were taken per well and from each picture the 30 biggest myotubes were measured (using Cell imaging software from Olympus); myotube diameters were determined as average from three independent measurements per myotube. Afterward, the 10 biggest myotubes from each picture were selected, and the means Ϯ SE were calculated for each well (i.e., mean of 40 biggest myotubes on the four pictures).
In vivo experiments. Female CB17/ICR-Prkdc scid /Crl mice (Scid mice; Charles River, Research Models and Services, Sulzfeld, Germany) aged 8 -9 wk were used. Animal experimentation was carried out according to the regulations effective in the Canton of Basel-City, Switzerland, and all protocols were approved by the Animal Welfare Committee of Novartis Institutes for Biomedical Research Basel. Myostatin propeptide D76A mutant was administered at a dose of 7.25 mg/kg ip on days 0, 3, 7, 14 , and 21 at a volume of 5 ml/kg. Body weights were determined at the start of the experiment (day 0) and two times per week thereafter. Twenty-eight days after the start of the experiment (day 0), mice were euthanized under CO 2 anesthesia. Serum and muscle samples were taken for analysis of muscle weight, CK activity, and serum myostatin activity.
Statistical analysis. Differences between groups were analyzed using one-way ANOVA for all experiments. Values were considered statistically significant at P Ͻ 0.05. Concentration-response data were evaluated by sigmoid curve fitting (Using XLfit software) yielding EC 50 values (concentrations causing half-maximal effects) and Emax (maximal effects). Body weight changes were determined against initial body weight taken at day 0 (first day of treatment).
RESULTS

Establishment of human skeletal myoblast (HuSkMC) system (by demonstrating inhibition of differentiation by myostatin, several other TGF-␤ family members, and by using an inhibitor of ALK4, 5, and 7 receptors
). An effort was made to find an in vitro muscle cell culture system that responded to myostatin at physiological levels and that would serve as a model for how myostatin might act in the human subject. Therefore, primary human myoblasts (HuSkMC) were used for this study. The effects on myogenic differentiation were assessed by attempting to differentiate HuSkMC in either the absence or presence of recombinant myostatin (1.0 ng/ml to 100 ng/ml), for 3 days after switching confluent myoblasts to differentiation media. The cultures were then fixed and stained with DAPI, to visualize nuclei, and were treated with antibodies to MyHC (Fig. 1A) . Myostatin treatment resulted in a decrease in both the size and the number of HuSkMC myotubes, and these decreases occurred in a concentration-dependent manner (Fig. 1, C and D) . Subsequent analysis of the fusion index and the diameters of the myotubes demonstrated that myostatin treatment inhibited the fusion index by up to 68% (Fig. 1C ) and inhibited the myotube diameter by up to 37% (Fig. 1D ). Moreover, CK activity, which increases during differentiation, is also reduced by myostatin, with an IC 50 of 0.59 ng/ml (Fig. 1B) and a maximal inhibition of 84% (Fig. 1E) .
We next analyzed the sensitivity of HuSkMC differentiation to other TGF-␤ family members: TGF-␤ 1 , GDF-11, activins, BMP-2, and BMP-7 ( Fig. 1B and data not shown). All of these proteins inhibited HuSkMC differentiation (Fig. 1B) . The rank order of potency was TGF-␤1 (IC 50 ϭ 0.20 ng/ml) Ն GDF-11 (0.23 ng/ml) Ͼ myostatin (0.59 ng/ml) Ͼ activin B (1.3 ng/ml, not shown) Ͼ activin AB (2.4 ng/ml; not shown) Ͼ activin A (5.0 ng/ml) Ն BMP-7 (5.6 ng/ml; not shown) Ͼ BMP-2 (29 ng/ml) (Fig. 1B ). These data demonstrate that multiple TGF-␤ family members can inhibit skeletal muscle differentiation, including some that have been previously shown to signal via Smads that are distinct from those activated by myostatin and GDF-11.
Finally, myogenic cells were shown to produce and release active myostatin and other TGF-␤ proteins, which can then act in an autocrine manner (36) . To determine the endogenous tone of myostatin-like activity in HuSkMC, these cells were switched into differentiation media and then were either left unperturbed, as control, or were treated with follistatin (1 g/ml), an inhibitor of myostatin, GDF-11, and activin, or with a pharmacologic inhibitor of the type I ALK receptors, SB-431542 (SB; 1 M). After 3 days, the degree of differentiation was assessed. Both follistatin and SB markedly increased both the number and size of HuSkMC myotubes, indicating facilitation of HuSkMC differentiation, and thus implying that the muscle cells autocrinely produce either myostatin or related molecules (Fig. 1, C and D) . The fusion index was increased by 50% to 75%, and myotube diameters were enlarged by 39% to 61% (Fig. 1C) . Also, CK activity was increased by 74% to 130% (Fig. 1E) . Moreover, both follistatin and SB significantly reduced inhibition of HuSkMC differentiation by myostatin (10 and 100 ng/ml) as indicated by increasing the fusion index, myotube diameter, and CK activity, above the levels seen in untreated differentiating myotubes (Fig. 1E) . These data demonstrate that HuSkMC differentiation is opposed by the autocrine production of myostatin and related molecules, and that myostatin can be blocked using a pharmacologic agent that inhibits ALK 4/5/7.
Inhibition of HuSkMC differentiation by TGF-␤ family members requires Smad2 and Smad3 signaling. Next, we sought to determine the relative contribution of Smad2 and Smad3 activation to the effects of myostatin and other TGF-␤ family members on HuSkMC differentiation. A phosphorylation-specific antibody demonstrated activation of Smad2/3 after an hour of treatment with myostatin, by both Western blot analysis ( Fig. 2A, left) and ELISA analysis, used to quantify Smad levels ( Fig. 2A, right) . Curve fitting of the phospho-Smad2 ELISA data yielded an IC 50 of 8.9 ng/ml, and a maximal increase in Smad phosphorylation of approximately eightfold ( Fig. 2A, right) . Similar induction of Smad2 phosphorylation was observed with other TGF-␤ family members (data not shown). To discriminate between the requirement for Smad2 and Smad3, HuSkMC were treated with siRNA directed against either gene, 24 h before differentiation, and then differentiated in the absence or presence of TGF-␤ membersor SB (Fig. 2, B and C) . Smad2 mRNA and protein levels were selectively reduced by siSmad2 treatment, as were Smad3 levels by siSmad3 treatment; furthermore, the siRNAs were demonstrated to be specific (Fig. 2B) . Knockdown of either Smad2 or Smad3 alone tended to reduce inhibition of HuSkMC differentiation by myostatin and TGF-␤1, but the concomitant knockdown of both Smad2 and Smad3 had an additive effect, as indicated by the significant rescue of fusion index, myotube diameter, and CK activity (Fig. 2C) . Similarly, inhibition of HuSkMC differentiation by GDF-11, activin A, or by BMP-7 was reduced after Smad2 and Smad3 knockdown. As a specificity control, a proinflammatory cocktail, consisting of IL-1␣, TNF-␣, and INF-␥, was used. The effects of this cocktail were not perturbed by the Smad siRNAs (data not shown). Myostatin inhibits the Akt pathway and can be opposed by IGF-1 treatment. IGF-1 has been characterized as a positive regulator of muscle differentiation, acting via the phosphatidylinositol 3-kinase/Akt pathway (10, 39) . We therefore were interested in determining whether myostatin might act by perturbing Akt signaling, as had been previously demonstrated in murine cardiac cells (32) , and, if so, whether IGF-1 treatment could oppose this effect. While the ALK inhibitor SB used as positive control significantly inhibited both basal levels of Smad2/3 phosphorylation, and those induced by myostatin (by up to 80%; Fig. 3A, left) , 24 h of IGF-1 treatment had no effect on myostatin-induced Smad2/3 phosphorylation (Fig.  3A, left; compare bars 3 and 8) . To analyze potential effects of IGF-I on Smad2/3 function, we assessed Smad reporter activity. IGF-1 treatment had no effect on myostatin-induced Smad reporter activity (Fig. 3C) , indicating that IGF-I could not oppose myostatin by these mechanisms.
Treatment of human myoblasts with myostatin for 24h decreased phosphorylation of Akt by up to 50% (Fig. 3A, right, and Fig. 3B, left, top row) . In addition to inhibiting Akt, myostatin decreased phosphorylation of p70S6 kinase and the pro-atrophy transcription factor FoxO1, both of which are normally phosphorylated by Akt (Fig. 3B, left) . However, Akt, p70S6 kinase, and FoxO1 phosphorylation were restored by treatment with IGF-1, indicating that IGF-1/Akt signaling is dominant over myostatin/Smad/Akt inhibition (Fig. 3B) . The and an immunoblot of Smad2/3 (right) from samples of HuSkMC that were treated with siRNA to either control (NTC, a scrambled sequence), Smad2 (siSmad2), Smad3 (siSmad3), or both, as indicated. HuSkMC were then differentiated into myotubes for 3 days. RT-PCR data are expressed as relative quantification (RQ) against NTC. Representative experiments are shown. C: analysis of fusion index, myotube diameter, and CK activity from HuSkMC myotubes differentiated for 3 days, treated with siRNA against Smad2 (siSmad2), Smad3 (siSmad3), or NTC. Twenty-four hours after siRNA treatment, HuSkMC were differentiated into myotubes for 3 days in the absence or presence of compounds. Data are expressed as percentage (fusion index), micrometer (myotube diameter), or mUnits/mg protein (CK activity). Shown are means Ϯ SE from 3 to 7 independent experiments. Differences from control (no compound in NTC group; first bar): *P Ͻ 0.05; differences from NTC: #P Ͻ 0.05. inhibition of Akt by myostatin could be blunted using siRNA to either Smad2 or Smad3 (not shown). Treatment with both siRNAs effectively restored Akt (Fig. 3B, right) and pFoxO signaling (data not shown). These data demonstrate both that myostatin blocks Akt signaling, and that IGF-1 can rescue Akt signaling without perturbing Smad2/3 activation by myostatin.
In addition to restoring Akt phosphorylation, IGF-1 also partially rescues the differentiation of myostatin-treated myoblasts, as determined by measuring fusion index, diameters (data not shown), and CK activity (Fig. 3D) . These data therefore suggest that myostatin's inhibition of differentiation might in part be due to its inhibition of Akt signaling, since restoration of Akt phosphorylation is coincident with the partial rescue of differentiation (Figs. 3D and 8) .
Role of Akt/TORC pathways in myostatin's inhibition of HuSkMC differentiation. Since myostatin signaling negatively regulates Akt, we sought to determine the contribution of the pathways downstream of Akt on myostatin signaling. To study the effects of the Akt/TORC pathways, we used siRNA against RICTOR to inhibit TORC2, and siRNA against RAPTOR to inhibit TORC1 (Figs. 4 and 8) . Treatment with RICTOR siRNA led to an inhibition of HuSkMC differentiation by itself, as indicated by a reduction in CK activity, by 28% (Fig.  4A) ; this blockade of differentiation was accompanied by an almost total inhibition of pAKT (Fig. 4B, fourth row, compare  lane 1 to lane 7) , as had been recently demonstrated in the setting of a muscle-specific deletion of RICTOR (20) . Inhibition of RICTOR caused an additive effect with myostatin, further inhibiting differentiation of HuSkMC myoblasts (Fig.  4A) , and a further reduction of pAkt, (Fig. 4B, fourth row,  compare lanes 1, 7, and 8) . Inhibition of RICTOR tended to also increase TGF-␤1 inhibition of both differentiation (Fig.  4A ), but did not reach statistical significance.
In contrast to siRNA to RICTOR, and as expected, siRNA inhibition of RAPTOR was not sufficient to decrease pAkt 473 , and if anything may somewhat increase pAkt (Fig. 4B, fourth  row, compare lanes 1 and 10, and Fig. 8 ), as recently reported (1) . While inhibition of RAPTOR by itself also did not block differentiation, it significantly facilitated myostatin's inhibitory action on differentiation (Fig. 4A) . Interestingly, in the presence of siRNA to RAPTOR there was a greater increase in pSmad2 than with myostatin alone (Fig. 4B, second row,  compare lanes 2 and 11) , indicating that blockade of Akt/ TORC1 positively feeds back to the myostatin pathway, increasing myostatin-induced activation of Smad2. In contrast, action of TGF-␤1 on either differentiation (Fig. 4A ) or pSmad2 signaling (Fig. 4B) was not significantly perturbed by siRNA to RAPTOR, indicating subtle differences in the mode of action between myostatin and TGF-␤1.
Myostatin reduces diameters of mature HuSkMC myotubes but does not induce the E3 ubiquitin ligases MuRF1 and
MAFbx. It had previously been reported that when active myostatin was delivered in adult mice, muscle atrophy was observed, as determined by a decrease in muscle mass and fiber diameter (52) . We therefore sought to determine the effect of myostatin on differentiated HuSkMC myotubes, and the mechanism by which this effect occurred. As a control for the ability to modify myotube diameter, IGF-1 was also used to treat HuSkMC myotube cultures (data not shown, but see Fig. 6A ). Myotubes were allowed to form for 3 days before treatments were initiated. As previously reported for both mouse (38) and human (16) myotubes, IGF-1 was able to induce significant myotube hypertrophy (data not shown, but see Fig. 6A ). In contrast, myostatin exposure resulted in a significant decrease in myotube diameter by up to 37% (Fig. 5A, photographs ; quantified in Fig. 5A, top bar graph) . The E3 ubiquitin ligases MuRF1 and MAFbx have been shown to be upregulated in multiple physiological settings of atrophy (12) . Therefore we next asked whether myostatin increases the expression of these genes, as had previously been reported (29) . Surprisingly, rather than an increase in expression, we observed a decrease in both MuRF1 and MAFbx levels, by up to 66% (Fig. 5B) ; only the highest concentrations of myostatin, 100 ng/ml, began to push expression back up toward that seen in unperturbed myotubes (Fig. 5B) . Since both MuRF1 and MAFbx are induced from very low levels, to their basal levels, upon muscle differentiation (data not shown), and since myostatin decreases differentiation when applied to myoblasts, we next asked whether the decrease in MuRF1 and MAFbx expression was a Fig. 4 . RAPTOR inhibition facilitates inhibitory effects of myostatin, but not TGF-␤1, on HuSkMC differentiation and Smad signaling. A: analysis of CK activity from HuSkMC myotubes differentiated for 3 days, treated with siRNA against RICTOR (siRIC), RAPTOR (siRAP), or NTC (scrambled siRNA, as a control). Twenty-four hours after siRNA treatment, HuSkMC were differentiated into myotubes for 3 days in the absence or presence of compounds. Data are expressed as mUnits/mg protein (CK activity). Shown are means Ϯ SE from 3 to 4 independent experiments. Differences from control (no compound in NTC group; first bar): *P Ͻ 0.05; differences from NTC: #P Ͻ 0.05. B: immunoblotting of pFoxO, pSmad2, and Smad2/3 (using an antibody that cross-reacts between total Smad2 and Smad3 proteins), pAkt, and Akt, from samples of HuSkMC treated with either scrambled siRNA (NTC, as a control), or with siRIC, siRAP, or siSmad2/3, starting 24 h before onset of differentiation.
sign of a more general blockade in differentiation-regulated genes. When applied to human myotubes, myostatin decreased CK activity up to 50% (Fig. 5A, bottom right) , and also the levels of myogenin and MyoD, by up to 82% (Fig. 5C ). These data are in line with a previous report that myostatin blocks muscle differentiation-associated gene expression in myotubes (9) , and extends those findings even to genes such as the pro-atrophy program. Therefore, instead of myostatin inducing the reported "atrophy pathway," it apparently causes a decrease in muscle mass by inhibiting the expression of genes required for muscle maintenance (Fig. 5C) .
ALK receptor inhibition or IGF-I treatment reduces myostatin's effects on differentiated HuSkMC myotubes.
To determine whether the myostatin-induced reduction in size of HuSkMC myotubes was caused by the ActRII/ALK receptor complex, we tested the ALK receptor inhibitor SB (Fig. 6A) . SB was able to block the decrease in myotube diameter caused by myostatin (Fig. 6A, compare bars 2 and 4) . Treatment of myotubes with SB alone caused an increase in myotube size by 21%. Myotubes treated with myostatin demonstrated a decrease in size by over 25%, which was opposed by simultaneous treatment with IGF-1 (Fig. 6A) . IGF-1 also blocked the decrease in expression of muscle-specific proteins, MyoD and myogenin, caused by myostatin as did the myostatin inhibitor, follistatin and SB (Fig. 6B) . In myotubes, IGF-1 blockade of myostatin's efficacy was again not at the level of Smad2/3, but rather by maintaining Akt signaling (Fig. 6C) . As was observed in myoblasts, myostatin was able to decrease Akt phosphorylation in a dose-responsive fashion in myotubes (Fig. 6C, right) . These data indicate that myostatin and IGF-1 have similar effects on differentiation markers and Akt signaling in both myoblasts and myotubes, resulting in distinct phenotypes (blockade of differentiation in myoblasts, vs. a decrease in myotube size in myotubes).
Increased muscle weight and CK activity by myostatin inhibition in vivo. We next performed in vivo studies to see whether it was possible to correlate the perturbation of CK activity with changes in muscle size, as had been observed in vitro. Scid mice were treated with the mutant myostatin D76A propeptide for 4 wk (Fig. 7A) . In the myostatin propeptide-treated group, body weight as well as the muscle weight of soleus (16%) , tibialis (9%), and quadriceps (9%) muscles were significantly increased compared with PBS-treated controls (Fig. 7A) . In addition, the weight of gastrocnemius (by 4%) and pectoralis (by 7%) muscles also tended to increase (Fig. 7A) without reaching statistical significance. Moreover, CK activity in gastrocnemius muscle lysates was significantly increased after application of myostatin D76A propeptide, suggesting increased differentiation of skeletal muscle in vivo (Fig. 7A) . Since myostatin has been shown to circulate in the bloodstream, we were interested in measuring its activity from serum samples as biomarker using a myostatin-responsive reporter (the gene plasmid pGL3-CAGA12-luc, transfected into HEK-293T cells). Scid mice were treated with a single dose of myostatin D76A propeptide, and serum samples were taken 24 h after treatment. To isolate the myostatin/GDF-11 component reporter, gene activity was measured in the presence of Fc-TGF-␤ RIIb (data not shown). In the myostatin propeptidetreated group, serum activity was reduced by 72% compared with PBS-treated controls (Fig. 7B) . 
DISCUSSION
In this study we report on the effects of myostatin and other TGF-␤ molecules on human skeletal myoblasts (HuSkMC) and myotubes. These HuSkMCs respond to myostatin at physiological concentrations, 0.1-300 ng/ml, resulting in a decrease in fusion index, myotube diameter, CK activity, and expression of MyoD and myogenin. It was previously demonstrated that follistatin, a more general inhibitor of TGF-␤ molecules, could induce an additive increase in muscle mass when combined with myostatin (25) . In this study, a range of other TGF-␤ molecules are shown to be able to block muscle differentiation, including the more distantly related activins, and BMP-2. This is an important demonstration, since many therapeutic approaches either in or heading toward the clinic are focused on myostatin alone. Myostatin's effects in the HuSkMC system were confirmed to be via ALK receptors, as had been previously shown in other systems, since SB, an inhibitor that targets ALKs 4, 5, and 7, can restore myostatin-inhibited differentiation.
Treatment with siRNAs that inhibit Smad2, Smad3, or both Smad2 and 3 simultaneously demonstrated that myostatin's antidifferentiation effects require both of these Smads; while inhibition of either Smad2 or Smad3 could blunt myostatin's effects, simultaneous blockade of both Smads had an additive effect. These results are in agreement with results from the Sandri group, published in a companion article (44a) .
We have previously shown that myotubes could be induced to hypertrophy by the IGF-1/Akt pathway, which induces protein synthesis required for muscle hypertrophy, and which blocks protein degradation ubiquitination pathways that are active during skeletal muscle atrophy (12) . Akt induces protein synthesis via the Akt/mTOR/p70S6K pathway (5, 38) (Fig. 8) . Furthermore, Akt blocks the upregulation of MuRF1 and MAFbx, by phosphorylating and inhibiting the FoxO family of transcription factors (43, 48) (Fig. 8) . MuRF1 and MAFbx encode E3 ubiquitin ligases, which are required for muscle atrophy (4).
In the current study, it was demonstrated that myostatin inhibits activation of Akt, in both myoblasts and myotubes. Akt signals via two mTOR signaling complexes, TORC1 and TORC2 (2) . It was recently reported that muscle-specific ablation of RAPTOR, but not RICTOR, results in a dystrophic phenotype (1); a separate group reported that a muscle-specific deletion of RICTOR impaired insulin-stimulated activation of the Akt pathway (20) . However, these signaling pathways had not been analyzed for their potential roles in myostatin signaling. In this study it was shown that inhibition of RICTOR, which is a component of TORC2, has a significant inhibitory effect on muscle differentiation by itself. Relevant to this finding, mice that are homozygous nulls for RICTOR die during embryogenesis, at day 10.5 of development, and these embryos were smaller than wild-type controls (15, 46) . The antidifferentiation effect of RICTOR that was observed is additive to that induced by myostatin, indicating that they may act independently of each other. In contrast, inhibition of RAPTOR, and thus TORC1, does not by itself block muscle differentiation, but does contribute to myostatin's inhibitory effects; this suggests a cooperation between the two on Akt, at the serine 473 phosphorylation site. Furthermore, inhibition of RAPTOR potentiates myostatin-induced Smad2 phosphorylation, establishing a feed-forward mechanism: myostatin activates Smad2, which is required to block Akt, inhibiting TORC1, which in turn potentiates myostatin's activation of Smad2. These findings are outlined in a signaling diagram (Fig. 8) .
Akt acts to inhibit the upregulation of the E3 ligases MuRF1 and MAFbx, which are required for skeletal muscle atrophy. When MuRF1 and MAFbx expression was assessed upon myostatin treatment of skeletal myotubes, we were surprised to see that these genes were in fact downregulated, along with myogenin, and MyoD. It is important to note that along with MyoD and myogenin, MuRF1 and MAFbx are induced upon muscle differentiation. Therefore, it appears that myostatin can block the induction of muscle's differentiation program, even when applied to already formed differentiated muscle cells. Combined with the decrease in Akt-induced protein synthesis signaling, myostatin's decrease in genetic differentiation programs would help to explain how it causes a decrease in skeletal muscle mass when applied to adult muscle.
Addition of IGF-1 was shown to block the effects of myostatin, when applied to either myoblasts or myotubes. This finding is consistent with prior data indicating that IGF-1 is both a positive modulator of differentiation, hypertrophy, and Akt signaling; however, it is of interest that IGF-1/Akt signaling is dominant over myostatin-induced inhibition of Akt. The precise intersection between the two pathways may be multifold, but the current study demonstrates that Akt is a particular nexus, and that IGF-1 can rescue the activation of Akt that is blunted by myostatin.
In vivo studies with an inhibitor of myostatin, the myostatin propeptide, demonstrated that CK activity could be increased by blocking myostatin, as occurred in vitro, and that this perturbation of differentiation correlates with myostatin inhibition's established increase in muscle mass in the murine model. The rather modest increases in muscle mass of ϳ15% were consistent with a prior study where myostatin was inhibited in adult animals. This confirms that much of the increase in mass observed in myostatin-null animals, where muscle is approximately twofold greater than in wild-type mice, is a function of developmental effects of the protein.
In summary, these data demonstrate that myostatin and its relatives are active on both myoblasts and myotubes, via a similar antidifferentiation mechanism, and that these phenotypes are mediated at least in part by perturbation of Akt/ TORC1 signaling. Furthermore, the demonstration that IGF-1 can dominantly overcome myostatin inhibition adds to the rationale for IGF-1-based treatment regimens in clinical settings where myostatin is active. Fig. 8 . Signaling diagram illustrating myostatin, TGF-␤, and IGF-1 pathway interactions. Myostatin's effects require both Smad2 and Smad3, which block muscle differentiation, including the E3 ligases MuRF1 and MAFbx, which are normally upregulated during muscle atrophy. This distinguishes the effects of myostatin with "typical atrophy." Smad2 and 3 activation are both required for myostatin's inhibitory effects on Akt. Inhibition of RAPTOR, and thus mammalian target of rapamycin (mTOR) complex 1 (TORC1), is additive with myostatin signaling. Smad2, 3 phosphorylation increases when RAPTOR is downregulated. RICTOR is itself sufficient to block differentiation. TGF-␤ family members that signal through the TGF-␤ type II receptor can also activate Smad2 and 3. Treatment with IGF-1 can counteract myostatin's antidifferentiation effects, indicating the IGF-1/Akt pathway is dominant over the myostatin pathway. p70S6K, p70 S6 kinase; ActRII, activin receptor II; PI3K, phosphatidylinositol 3-kinase; PIP3, phosphatidylinositol-3, 4, 5-trisphosphate.
